Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

3157 - Efficacy and safety of anlotinib in advanced leiomyosarcoma: Subgroup analysis of a phase IIB trial (ALTER0203)

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Tumour Site

Sarcoma

Presenters

Yihebali Chi

Citation

Annals of Oncology (2019) 30 (suppl_5): v683-v709. 10.1093/annonc/mdz283

Authors

Y. Chi1, Y. Yao2, Z. Fang3, S. Wang4, G. Huang5, Q. Cai6, G. Shang7, G. Wang8, G. Qu9, Q. Wu10, Y. Jiang11, J. Song12, J. Chen13, X. Zhu14, Z. Cai15, C. Bai16, Y. Lu17, Z. Yu18, J. Shen19, J. Cai20

Author affiliations

  • 1 Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 - Beijing/CN
  • 2 Medical Oncology, Affiliated Sixth People’s Hospital, Shanghai Jiaotong University, shanghai/CN
  • 3 Orthopedics & Soft Tissue Department, Peking University Cancer Hospital, 100142 - Beijing/CN
  • 4 Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou/CN
  • 5 Orthopedics & Soft Tissue Department, Hunan Cancer Hospital, changsha/CN
  • 6 Department Of Bone And Soft Tissue, Henan Cancer Hospital, Zhengzhou/CN
  • 7 Orthopedics & Soft Tissue Department, Liaoning Cancer Hospital and Institute, shenyang/CN
  • 8 Orthopedics & Soft Tissue Department, Tianjin Medical University Cancer Institute & Hospital, Tianjin/CN
  • 9 Orthopedic Surgery, Harbin Medical University Cancer Hospital, Harbin/CN
  • 10 Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu/CN
  • 11 Department Of Medical Oncology, Cancer Center, State Key Laboratory Of Biotherapy, West China Hospital, Sichuan University, 610041 - Chengdu/CN
  • 12 Orthopedics & Soft Tissue Department, Gansu Provincial Cancer Hospital, Lanzhou/CN
  • 13 Cancer Center, Wuhan Union Hospital, Wuhan/CN
  • 14 Department Of Orthopedics, Arthrosis & Sports Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou/CN
  • 15 Department Of Orthopedics, The First People’s Hospital Affiliated to Shanghai Jiaotong University, Shanghai/CN
  • 16 Medical Oncology, Peking Union Medical College Hospital/ Chinese Academy of Medical Sciences, Beijing/CN
  • 17 Department Of Breast And Bone Soft Tissue Tumors, Guangxi Medical University Affiliated Tumor Hospital, Nanning/CN
  • 18 Orthopedics Department, Jiangxi Cancer Hospital, Nanchang/CN
  • 19 Department Of Bone Tumor, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou/CN
  • 20 Department Of Hepatobiliary Surgery, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 100021 - Beijing/CN
More

Resources

Abstract 3157

Background

Leiomyosarcoma (LMS) is one of the most common pathologic subtypes of soft tissue sarcoma (STS) with limited treatment options. An earlier analysis in ALTER0203 showed efficacy and safety of anlotinib in overall subtype of STS. Here we report subgroup analysis of the patients with Leiomyosarcoma in ALTER0203.

Methods

Key inclusion criteria: aged from 18 to 70, confirmed histological diagnosis of advanced LMS, angiogenesis inhibitor naive, progressing after anthracycline-contained chemotherapy, measurable disease (RECIST 1.1), ECOG performance status (PS) 1-2. Anlotinib 12 mg per day 2 weeks on and 1 week off or placebo was given after 2:1 randomization. Primary endpoint: progression-free survival (PFS). Secondary endpoints: overall response rate (ORR), disease control rate (DCR) and so on.

Results

41 eligible LMS patients, 9 males (21.95%), median age 49 (range 28-66), received either anlotinib (n = 27) or placebo (n = 14). The median PFS was 1.43 months for placebo and 5.83 months for anlotinib (P<0.0001). CR or PR was not observed for both placebo and anlotinib. SD was 2/14 for placebo versus 16/27 for anlotinib (P = 0.01). The most common adverse events (AEs) were hypertension, elevated TSH, hypertriglyceridaemia. The most common grade 3 or higher AEs were hypertension, gamma glutamyl transferase elevation, hyponatremia.Table:

1693P

EfficacyAlotinib (n = 27)Placebo (n = 14)P-value
mPFS (mos)5.831.43< 0.0001
HR(95%CI)2.85-8.811.41-1.45
ORR, n(%)0(0%)0(0%)N/A
DCR, n(%)16(59.26%)2(14.29%)0.01
The most common AEs, n(%)
Hypertension20(74.07%)1(7.14%)< 0.0001
TSH elevation19(70.37%)0(0%)< 0.0001
Hypertriglyceridaemia13(48.15%)4(28.57%)0.32
Grade≥3 AEs, n(%)
Hypertension5(18.52%)0(0%)< 0.0001
Gamma glutamyl transferase elevation2(7.41%)1(7.14%)1.0
Hyponatremia2(7.41%)0(0%)0.54

Conclusions

Anlotinib not only improves PFS and DCR significantly, but also presents good safety in patients with LMS, which suggests that anlotinib could be an option for LMS patients.

Clinical trial identification

NCT02449343.

Editorial acknowledgement

Legal entity responsible for the study

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Funding

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.